N3

General Information


DRACP ID  DRACP02415

Peptide Name   N3

Sequence  RKILILIKRK

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
U-937 Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia Leukemia LD50>64 µM; MTC>64 µM CytoTox 96 non-radiactive cytotoxicity assay  2 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02415

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C60H117N19O11

Absent amino acids  ACDEFGHMNPQSTVWY

Common amino acids  IK

Mass  144143

Pl  12.55

Basic residues  5

Acidic residues  0

Hydrophobic residues  5

Net charge  5

Boman Index  -2189

Hydrophobicity  4

Aliphatic Index  195

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25192319

Title  Rational design of artificial β-strand-forming antimicrobial peptides with biocompatible properties

Doi 10.1021/mp500271c

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_8968

DRACP is developed by Dr.Zheng's team.